RBBP6 and intrahepatic cholangiocarcinoma: In summary, circPCSK6‐167aa effectively inhibits the ubiquitination of IκBα by competitively binding to RBBP6 and then orchestrates the inhibition of NF‐κB pathway activation, ultimately preventing the malignant biological behavior of ICC.